GHAPPcast

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
  • 0,0 (0)
  • Y HỌC
GHAPPcast

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

  1. 2 NGÀY TRƯỚC

    Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?

    In this video, Anne Feldman, NP, from Cleveland Clinic, discusses Guselkumab (Tremfya), an FDA-approved treatment for adults with moderate to severe ulcerative colitis, plaque psoriasis, and psoriatic arthritis. With promising Phase 3 clinical trial results, Guselkumab is expected to receive FDA approval for Crohn’s disease, making it a potential first-line advanced therapy or an option for patients who have failed other advanced treatments. Beyond gut-related inflammation, extraintestinal manifestations (EIMs)—affecting the skin, joints, and eyes—are common in IBD (Inflammatory Bowel Disease), especially Crohn’s disease. Up to 40% of IBD patients experience EIMs, sometimes even before their IBD diagnosis. Because Guselkumab is already FDA-approved for psoriasis and psoriatic arthritis, it offers a multisystem treatment approach, addressing both IBD and associated autoimmune conditions. By targeting multiple inflammatory pathways, this therapy has the potential to reduce disease burden and significantly improve quality of life. For more information on IBD treatment strategies and Guselkumab’s role in patient care, visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website or download the GHAPP ACE mobile app.

    3 phút

  2. 3 NGÀY TRƯỚC

    KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?

    In this video, Sherona Bau, NP, at Pfleger Institute at UCLA, shares the latest advancements in cirrhosis management, including newly FDA-approved medications and updated AASLD (American Association for the Study of Liver Diseases) guidelines. While there are still limited medications specifically for cirrhosis, recent developments provide promising options for patients with liver disease. One key update is in the management of portal hypertension, where AASLD now recommends non-selective beta blockers like carvedilol for variceal bleeding prophylaxis, particularly due to its vasodilatory effects. Patients with medium or large varices are advised to take these medications to reduce bleeding risks. Another significant procedure being emphasized is the TIPS (Transjugular Intrahepatic Portosystemic Shunt), which is considered for patients with recurrent variceal bleeding or refractory ascites. However, it is generally preferred for those already on a liver transplant list, as there is a small risk of liver failure. There have also been notable advancements in treating Primary Biliary Cholangitis (PBC) with two newly FDA-approved medications: Ivarix (approved June 10) and Cadazopa (approved August 14). While these treatments are not approved for decompensated cirrhosis, they are safe for Child-Pugh Class A patients, though providers are advised to discontinue treatment if the disease progresses to Child-Pugh Class B or C. Additionally, for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH), the FDA recently approved Rivumet on April 9, marking the first-ever FDA-approved therapy for MASH with liver fibrosis (F2-F3). Although it is not yet approved for cirrhotic patients, further data is expected soon. As liver disease management continues to evolve, staying informed on new treatments and best practices is crucial for improving patient outcomes. For more details, visit the GHAPP website and subscribe for expert insights on liver disease care!

    3 phút

  3. 4 NGÀY TRƯỚC

    Journal Club: Guselkumab as Maintenance Therapy for Ulcerative Colitis- Phase 3 QUASAR Study Results

    In this video, Shayla Schoenoff, PA-C, reviews the Phase 3 QUASAR maintenance study, evaluating the efficacy and safety of Guselkumab as a maintenance therapy for moderately to severely active ulcerative colitis. This randomized, double-blind, placebo-controlled study assessed patients who previously had an inadequate response to conventional or advanced therapies and demonstrated a clinical response to GUS IV induction therapy. Key findings show that GUS subcutaneous maintenance therapy significantly improved clinical remission rates, symptomatic remission, endoscopic improvement, and steroid-free remission at Week 44 compared to placebo. Patients receiving 100 mg GUS every 8 weeks and 200 mg GUS every 4 weeks showed higher remission rates, with 50% of patients in the 200 mg group achieving clinical remission, compared to 18.9% in the placebo group. Additionally, 69% of GUS-treated patients in clinical remission also achieved endoscopic remission, reinforcing its effectiveness in managing ulcerative colitis. The study also evaluated safety outcomes, showing that the proportion of patients experiencing adverse events was similar across treatment groups. The most common adverse events included COVID-19, ulcerative colitis flare-ups, and arthralgia, with no cases of death, active tuberculosis, anaphylaxis, or serious hepatic adverse events reported. This comprehensive review provides essential insights into GUS maintenance therapy, highlighting its role in long-term ulcerative colitis management. Watch now for a detailed breakdown of the study results, and don’t forget to subscribe for more updates on IBD treatments and clinical trials. Visit the GHAPP website or download the GHAPP ACE app for more information and educational content.

    6 phút

  4. 5 NGÀY TRƯỚC

    FAQ: What should patients know about living with cirrhosis?

    In this video, Janet Gripshover, CRNP, Nurse Manager at Cedars-Sinai Liver Transplant Program, discusses essential steps for managing cirrhosis to improve quality of life and longevity. The most critical action for anyone living with liver disease is to completely eliminate alcohol consumption, as alcohol accelerates liver damage, increases fibrosis, and raises the risk of decompensated cirrhosis, which can severely impact daily functioning and overall health. A low-sodium, high-protein diet is also vital for cirrhosis management. Reducing sodium intake helps prevent fluid retention, which can cause discomfort, swelling, and difficulty breathing. Adequate protein intake—about 1.2 grams per kilogram of body weight—is crucial to prevent muscle loss often associated with cirrhosis. Since the body struggles to absorb protein efficiently, maintaining proper nutrition and engaging in strength training can help preserve lean muscle mass and overall strength. Regular exercise and staying active play a crucial role in supporting liver function and overall health. Additionally, individuals with cirrhosis should ensure they are up to date on preventive health screenings, including mammograms, prostate exams, and colonoscopies, especially if a liver transplant is a future consideration. Watch this video to learn more about cirrhosis management and practical steps to enhance your health. For additional resources, visit the GHAPP website or download the GHAPP ACE app on iOS and Android. #Cirrhosis #LiverHealth #LiverDisease #CirrhosisManagement #TransplantCare #Hepatology #LiverTransplant #HealthyLiving #LowSodiumDiet #HighProteinDiet #PreventiveCare

    4 phút

  5. 13 THG 2

    FAQ: What are predictive risk factors for disease severity in CD and UC?

    In this FAQ video module, Erin Darguzas, NP, Gastroenterology Specialist at Northwestern Medicine, discusses the predictive risk factors for disease severity in Crohn’s disease and ulcerative colitis. Over the past 15 years, researchers have identified multiple prognostic factors that can help predict disease progression and guide individualized IBD management. For moderate to severe Crohn’s disease, key factors include age at diagnosis (before 40), disease location (small bowel, colonic, or upper GI involvement), and disease behavior (structuring, penetrating, or perianal disease). Additional concerns include deep ulcers on endoscopy, significant weight loss, low albumin levels, smoking history, and genetic markers. For ulcerative colitis, predictors of severity include age at diagnosis (before 50), frequency of disease flares, need for frequent therapy changes, and failure to achieve endoscopic remission. Pathology findings, such as persistent neutrophil infiltration, and treatment adherence history are also crucial in determining long-term outcomes. Early identification of these prognostic factors allows for a more personalized treatment approach, improving patient outcomes in inflammatory bowel disease (IBD) management. Watch this video to learn more about Crohn’s disease and ulcerative colitis risk factors. For additional resources, visit the GHAPP website or download the GHAPP ACE app.

    3 phút

  6. 12 THG 2

    What lifestyle changes are essential for managing cirrhosis effectively?

    In this video, Sherona Bau, NP, from the Pfleger Liver Institute at UCLA, discusses the essential lifestyle changes for effectively managing cirrhosis. Maintaining a healthy lifestyle is key to slowing disease progression and preventing complications. One of the most critical recommendations is completely avoiding alcohol, as it accelerates liver damage and increases the risk of decompensation. A low-sodium diet is also essential, with a daily limit of no more than 2,000 mg of sodium to help reduce fluid retention, leg swelling, and abdominal ascites. Patients should avoid processed and canned foods, which are often high in sodium, and eliminate raw or undercooked shellfish to prevent infections. Additionally, reducing sugary drinks, refined sugar, and red meat intake can support overall liver health. It’s also important to avoid NSAIDs (nonsteroidal anti-inflammatory drugs), as they can increase the risk of kidney injury, and refrain from using herbal supplements without consulting a healthcare provider. Lastly, regular physical activity—such as walking 20 to 30 minutes daily—can help maintain overall health and improve disease outcomes. Making these lifestyle changes can significantly improve quality of life and liver function for patients with cirrhosis. Watch this video for expert insights, and visit the GHAPP website or download the GHAPP ACE app for more information.

    2 phút

  7. 11 THG 2

    Journal Club: Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results

    In this video, Jamie Brogan, NP, from Northwestern Medicine in Chicago, discusses the efficacy and safety of Guselkumab therapy for patients with moderate to severely active Crohn’s disease, highlighting results from the Galaxy 2 and Galaxy 3 trials. Guselkumab is a dual-acting IL-23p19 subunit inhibitor, designed to neutralize IL-23 and bind to the CD64 receptor, which plays a role in the production of IL-23. The Galaxy 2 and 3 Phase 3 trials used a randomized, double-blind, double-dummy treat-through design to evaluate IV induction and subcutaneous maintenance therapy in Crohn’s patients. The co-primary endpoints included clinical response at Week 12 and clinical remission at Week 48, along with clinical response at Week 12 and endoscopic response at Week 48. Achieving endoscopic response is particularly significant, as it has been shown to reduce disease progression, flares, hospitalizations, and the need for surgery. The study results showed strong efficacy for Guselkumab therapy. In Galaxy 2, 49% to nearly 55% of Guselkumab patients achieved clinical response at Week 12 and remission at Week 48, compared to 11.8% on placebo. In Galaxy 3, 46.9% and 48% of Guselkumab patients met the same criteria, compared to 12.2% on placebo. Additionally, Guselkumab met all secondary endpoints and demonstrated superiority to ustekinumab at Week 48 for endoscopic response, endoscopic remission, and deep remission. The safety profile of Guselkumab therapy remained consistent and favorable. The most common adverse events reported were COVID-19, upper respiratory infections, Crohn’s disease worsening, arthralgia, and headache, with no deaths observed. These results underscore Guselkumab’s potential as an effective maintenance therapy for Crohn’s disease. Watch this video for an in-depth analysis, and visit the GHAPP website or download the GHAPP ACE app for more details.

    5 phút

  8. 10 THG 2

    FAQ: How Can You Support a Shared Decision-Making Process With the Patient?

    In this video, Allison Moser, a transplant hepatology nurse practitioner at Rush University Medical Center, discusses the key principles of shared decision-making and how healthcare providers can better support their patients in making informed choices about their care. Shared decision-making is a collaborative approach that prioritizes communication, respect, and patient autonomy, ensuring that treatment decisions align with the patient’s values and preferences. Effective shared decision-making begins with active listening—understanding the patient’s concerns, goals, and priorities. It also involves clear communication, providing easy-to-understand explanations of treatment options, risks, and benefits. Visual aids and simple language can help improve comprehension, allowing patients to make well-informed decisions. Healthcare providers play a crucial role in guiding patients through their options, acknowledging uncertainties, and reassuring them that it’s okay to take time or seek second opinions. By fostering a trusting partnership, providers can empower patients to take an active role in their health journey, leading to better engagement, satisfaction, and health outcomes. Watch the full video to learn how to implement shared decision-making in clinical practice. For more expert insights, visit the GHAPP website and subscribe for more healthcare discussions!

    3 phút
Xem tất cả (63)

Giới Thiệu

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

Thông Tin

  • Nhà sáng tạo
    Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
  • Năm hoạt động
    2023 - 2025
  • Tập
    63
  • Xếp hạng
    Sạch
  • Bản quyền
    © 2025 GHAPPcast
  • Trang web chương trình
    GHAPPcast

Có Thể Bạn Cũng Thích

Bạn cần đăng nhập để nghe các tập có chứa nội dung thô tục.

Luôn cập nhật thông tin về chương trình này

Đăng nhập hoặc đăng ký để theo dõi các chương trình, lưu các tập và nhận những thông tin cập nhật mới nhất.
Chọn quốc gia hoặc vùng

Châu Phi, Trung Đông và Ấn Độ

Châu Á Thái Bình Dương

Châu Âu

Châu Mỹ Latinh và Caribê

Hoa Kỳ và Canada